Hearing Loss After the First Low Dose Administration of Cisplatin
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, vol.32, no.9, pp.1216-1218, 2022 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 32 Issue: 9
- Publication Date: 2022
- Doi Number: 10.29271/jcpsp.2022.09.1216
- Journal Name: JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
- Page Numbers: pp.1216-1218
- Open Archive Collection: AVESIS Open Access Collection
- Karadeniz Technical University Affiliated: Yes
Abstract
Cisplatin is commonly used antineoplastic drug that is effective against different types of tumours. Nephrotoxicity, neurotoxicity, and ototoxicity constitute the main dose-limiting side effects of the drug. We present a case of sensorineural hearing loss after the first low dose of cisplatin. Five days after receiving an intravenous 30 mg/day at 120 minutes, the patient presented with serious bilateral sensorineural hearing loss. Cisplatin-induced hearing impairment is generally dose-related and cumulative; however, the toxicity can occur after the first dose without a cumulative high-dose and can be irreversible.